Interventional therapies for hepatocellular carcinoma

Cancer Imaging

Volumn 12, Issue 1, 2012, Pages 79-88

  Willatt, Jonathon M ^a   Francis, Isaac R ^a   Novelli, Paula M ^a   Vellody, Ranjith ^a   Pandya, Amit ^a   Krishnamurthy, V N ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Embolization; Hepatocellular carcinoma; Radiofrequency ablation

Indexed keywords

ALCOHOL; CISPLATIN; DOXORUBICIN; IODINATED POPPYSEED OIL; IODINE 131; MACROSALB TC 99M; MITOMYCIN C; YTTRIUM 90;

ABDOMINAL PAIN; ARTERY CATHETERIZATION; BILE DUCT INJURY; BILE LEAKAGE; BURN; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED RELEASE FORMULATION; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; DRUG ELUTING BEAD; FEVER; GASTRITIS; GASTRODUODENAL ULCER; HEMOPERITONEUM; HEPATIC ARTERY; HUMAN; ILEUS; INFERIOR CAVA VEIN; LIVER ABSCESS; LIVER ANGIOGRAPHY; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER HEMORRHAGE; LIVER TOXICITY; LIVER TRANSPLANTATION; LOCAL THERAPY; META ANALYSIS; MINIMALLY INVASIVE PROCEDURE; NAUSEA; PANCREATITIS; PNEUMONIA; PORTAL VEIN THROMBOSIS; RADIATION DOSE; RADIATION INJURY; RADIOFREQUENCY ABLATION; RADIOLOGIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; THERMAL INJURY; TREATMENT PLANNING; TUMOR ABLATION; TUMOR RECURRENCE; TUMOR SEEDING; TUMOR VOLUME; VOMITING;

ALGORITHMS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DRUG IMPLANTS; ETHANOL; ETHIODIZED OIL; HEPATECTOMY; HEPATIC ARTERY; HUMANS; INJECTIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING, INTERVENTIONAL; MICROSPHERES; NEOPLASM STAGING; RADIOGRAPHY, INTERVENTIONAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SCLEROTHERAPY; SURGICAL PROCEDURES, MINIMALLY INVASIVE; YTTRIUM RADIOISOTOPES;

EID: 84860196108     PISSN: None     EISSN: 14707330     Source Type: Journal    
DOI: 10.1102/1470-7330.2012.0011     Document Type: Review

References (80)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(Suppl 1): S5-16. doi:10.1053/j.gastro.2004.09.011.
2. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004; 127: 1372-80. doi:10.1053/j.gastro.2004.07.020. (Pubitemid 39457763)
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-49. doi:10.3322/caac.20006.
4. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127(Suppl 1): S35-50. doi:10.1053/j.gastro.2004.09.014. (Pubitemid 39423368)
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17. doi:10.1016/S0140-6736(03)14964-1. (Pubitemid 37518510)
6. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817-23.
7. Ohata K, Hamasaki K, Toriyama K, et al. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43. doi:10.1002/cncr.11427. (Pubitemid 36676258)
8. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001; 96: 2462-7. doi:10.1111/j.1572-0241.2001.04054.x. (Pubitemid 32769212)
9. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13. doi:10.1053/jhep.2002.36780. (Pubitemid 35253437)
10. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol 2004; 40: 124-31. doi:10.1016/j.jhep.2003.09.027. (Pubitemid 38064721)
11. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74. doi:10.1055/s-0030-1247133.
12. Huang YH, Chen CH, Chang TT, et al. Evaluation of predictive value of CLIP, Okuda, TNM and JIS staging systems for hepatocellular carcinoma patients undergoing surgery. J Gastroenterol Hepatol 2005; 20: 765-71. doi:10.1111/j.1440-1746.2005.03746.x. (Pubitemid 40733373)
13. Sherman M. Hepatocellular carcinoma: screening and staging. Clin Liver Dis 2011; 15: 323-34. doi:10.1016/j.cld.2011.03.003.
14. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36. doi:10.1002/hep.20933. (Pubitemid 43112690)
15. Llovet JM. Treatment of hepatocellular carcinoma. Curr Treat Options Gastroenterol 2004; 7: 431-41. doi:10.1007/s11938-004-0002-8. (Pubitemid 39585737)
16. Schwarz RE, Smith DD. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 2008; 195: 829-36. doi:10.1016/j.amjsurg.2007.10.010. (Pubitemid 351749460)
17. Kim YN, Rhim H, Choi D, et al. The effect of radiofrequency ablation on different organs: ex vivo and in vivo comparative studies. Eur J Radiol 2011; 80: 526-32. doi:10.1016/j.ejrad.2009.11.011.
18. Poon RT, Fan ST, Tsang FH, Wong J. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective. Ann Surg 2002; 235: 466-86. doi:10.1097/00000658-200204000-00004. (Pubitemid 34258345)
19. Buscarini L, Buscarini E, Di Stasi M, Vallisa D, Quaretti P, Rocca A. Percutaneous radiofrequency ablation of small hepatocellular carcinoma: long-term results. Eur Radiol 2001; 11: 914-21. doi:10.1007/s003300000659. (Pubitemid 32755549)
20. Livraghi T, Goldberg SN, Lazzaroni S, et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000; 214: 761-8. (Pubitemid 30115377)
21. Lam VW-T, Ng KK, Chok KS, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008; 207: 20-9. doi:10.1016/j.jamcollsurg.2008.01.020.
22. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995; 197: 101-8.
23. Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma
24. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 1999; 210: 655-61. (Pubitemid 29124024)
25. Chen M-S, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006; 243: 321-8. doi:10.1097/01.sla. 0000201480.65519.b8. (Pubitemid 43327762)
26. Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan Criteria. Ann Surg 2010; 252: 903-12. doi:10.1097/SLA.0b013e3181efc656.
27. Huang G-T, Lee PH, Tsang YM, et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 2005; 242: 36-42. doi:10.1097/01.sla.0000167925. 90380.fe. (Pubitemid 40917965)
28. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003; 228: 235-40. doi:10.1148/radiol.2281020718. (Pubitemid 36736097)
29. Orlando A, Leandro G, Olivo M, Andriulli A, Cottone M. Radiofrequency thermal ablation vs. percutaneous ethanol injection for small hepatocellular carcinoma in cirrhosis: meta-analysis of randomized controlled trials. Am J Gastroenterol 2009; 104: 514-24. doi:10.1038/ajg.2008.80.
30. Ruzzenente A, Guglielmi A, Sandri M, et al. Surgical resection versus local ablation for hcc on cirrhosis: results from a propensity case-matched study. J Gastrointest Surg 2012; 16: 301-11. doi:10.1007/s11605-011-1745-x.
31. Brown KT, Nevins AB, Getrajdman GI, et al. Particle embolization for hepatocellular carcinoma. J Vasc Interv Radiol 1998; 9: 822-8. doi:10.1016/S1051-0443(98)70398-7. (Pubitemid 28427845)
32. Covey AM, Maluccio MA, Schubert J, et al. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy. Cancer 2006; 106: 2181-9. doi:10.1002/cncr.21883. (Pubitemid 43673240)
33. Konno T, Maeda H, Iwai K, et al. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 1983; 19: 1053-65. doi:10.1016/0277-5379(83)90028-7. (Pubitemid 13045311)
34. Nakakuma K, Tashiro S, Hiraoka T, et al. Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 1983; 52: 2193-200. doi:10.1002/1097-0142(19831215)52: 12<2193::AIDCNCR2820521203>3.0.CO;2-R. (Pubitemid 14205933)
35. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54. doi:10.1148/radiol.2241011262. (Pubitemid 34680374)
36. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25. doi:10.1007/s00270-006-0062-3. (Pubitemid 44900485)
37. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol 1993; 4: 741-7. doi:10.1016/S1051-0443(93)71965-X.
38. Kawai S, Okamura J, Ogawa M, et al. Prospective and randomized clinical trial for the treatment of hepatocellular arcinoma - a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 1992; 31(Suppl): S1-6. doi:10.1007/BF00687096.
39. Geschwind JF, Ramsey DE, Cleffken B, et al. Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 2003; 26: 111-17. doi:10.1007/s00270-002-2524-6. (Pubitemid 36919549)
40. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004; 101: 796-802. doi:10.1002/cncr.20426. (Pubitemid 39030937)
41. Kothary N, Weintraub JL, Susman J, Rundback JH. Transarterial chemoembolization for primary hepatocellular carcinoma in patients at high risk. J Vasc Interv Radiol 2007; 18: 1517-26; quiz 1527. doi:10.1016/j.jvir.2007.07. 035.
42. Aoki T, Imamura H, Hasegawa K, et al. Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004; 139: 766-74. (Pubitemid 38886514)
43. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9. doi:10.1053/j.gastro.2006.05. 021. (Pubitemid 44142456)
44. Poon RT, Tso WK, Pang RW, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intraarterial drug-eluting bead. Clin Gastroenterol Hepatol 2007; 5: 1100-8. doi:10.1016/j.cgh.2007.04.021.
45. Bruix J, Llovet JM, Castells A, et al. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998; 27: 1578-83. doi:10.1002/hep.510270617. (Pubitemid 28264682)
46. d'Etude G. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1256-61.
47. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9. doi:10.1016/S0140-6736(02)08649-X. (Pubitemid 34607087)
48. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30. doi:10.1016/S0168-8278(01)00130-1. (Pubitemid 32844200)
49. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42. doi:10.1053/jhep.2003.50047. (Pubitemid 36152543)
50. Doffoël M. Multicentre randomised phase III trial comparing tamoxifen alone or with transarterial lipiodol chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients. Eur J Cancer 2008; 44: 528-38.
51. Lo C-M. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinom. Hepatology 2002; 35: 1164-71. doi:10.1053/jhep.2002.33156. (Pubitemid 34454013)
52. Pelletier G. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998; 29: 129-34. doi:10.1016/S0168-8278(98)80187-6. (Pubitemid 28307992)
53. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; CD004787.
54. Chan K-L. High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. Cancer 2002; 94: 3179-85. doi:10.1002/cncr.10612. (Pubitemid 34670501)
55. Chung JW. Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 1996; 198: 33-40.
56. Martin R, Irurzun J, Munchart J, et al. Optimal technique and response of doxorubicin beads in hepatocellular cancer: bead size and dose. Korean J Hepatol 2011; 17: 51-60. doi:10.3350/kjhep.2011.17.1.51.
57. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101: 476-80.
58. Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol 2008; 31: 1141-9. doi:10.1007/s00270-008-9409-2.
59. Malagari K, Chatzimichael K, Alexopoulou E, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31: 269-80. doi:10.1007/s00270-007-9226-z.
60. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009; 15: 526-32. doi:10.1097/PPO.0b013e3181c5214b.
61. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81. doi:10.1016/j.jhep.2006.10.020. (Pubitemid 46201723)
62. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52. doi:10.1007/s00270-009-9711-7.
63. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-51. doi:10.1007/s00270-009-9750-0.
64. Liapi E, Geschwind JF. Transcatheter arterial chemoembolization for liver cancer: is it time to distinguish conventional from drug-eluting chemoembolization? Cardiovasc Intervent Radiol 2011; 34: 37-49. doi:10.1007/s00270-010-0012-y.
65. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116: 1305-14. doi:10.1002/cncr.24884.
66. Vente MA, Wondergem M, van der Tweel I, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol 2009; 19: 951-9. doi:10.1007/s00330-008-1211-7.
67. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21: 224-30. doi:10.1016/j.jvir.2009.10.013.
68. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64. doi:10.1053/j.gastro. 2009.09.006.
69. Woodall CE, Lewandowski RJ, Mulcahy MF, et al. Is selective internal radioembolization safe and effective for patients with inoperable hepatocellular carcinoma and venous thrombosis? J Am Coll Surg 2009; 208: 375-82. doi:10.1016/j.jamcollsurg.2008.12.009.
70. Kulik LM, Atassi B, van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-86. doi:10.1002/jso.20609. (Pubitemid 44851918)
71. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 2009; 9: 1920-8. doi:10.1111/j.1600-6143. 2009.02695.x.
72. Riaz A, Kulik L, Lewandowski RJ, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009; 49: 1185-93. doi:10.1002/hep.22747.
73. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47: 71-81. doi:10.1002/hep.21980. (Pubitemid 351171043)
74. Salem R, Lewandowski R, Roberts C, et al. Use of yttrium-90 glass microspheres (TheraSphere) for the treatment of unresectable hepatocellular carcinoma in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15: 335-45. doi:10.1097/01.RVI.0000123319.20705.92. (Pubitemid 38451976)
75. Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1377-84. doi:10.1016/j.jvir.2010.04.027.
76. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005; 235: 469-77. doi:10.1148/radiol.2352031856. (Pubitemid 40571084)
77. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediatesized hepatocellular carcinoma. Cancer 2010; 116: 5452-60. doi:10.1002/cncr.25314.
78. Liao GS, Yu CY, Shih ML, et al. Radiofrequency ablation after transarterial embolization as therapy for patients with unresectable hepatocellular carcinoma. Eur J Surg Oncol 2008; 34: 61-6.
79. Virmani S, Harris KR, Szolc-Kowalska B, et al. Comparison of two different methods for inoculating VX2 tumors in rabbit livers and hind limbs. J Vasc Interv Radiol 2008; 19: 931-6. doi:10.1016/j.jvir.2008.02.019.
80. Wang L, Harris KR, Szolc-Kowalska B, et al. Post-processing of dynamic gadolinium-enhanced magnetic resonance imaging exams of the liver: explanation and potential clinical applications for color-coded qualitative and quantitative analysis. Acta Radiol 2008; 49: 6-18. doi:10.1080/02841850701630300.